JAK1 and non-small cell lung carcinoma: Moreover, JAK1/2 inhibitors, namely AZD1480 for the treatment of solid tumors and Momelotinib that treats non-small cell lung cancer, resulted in clinical trial termination due to neurotoxicity and neutropenia, respectively [NCT01112397, NCT02206763].